Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P42704
UPID:
LPPRC_HUMAN
Alternative names:
130 kDa leucine-rich protein; GP130
Alternative UPACC:
P42704; A0PJE3; A8K1V1; Q53PC0; Q53QN7; Q6ZUD8; Q7Z7A6; Q96D84
Background:
The Leucine-rich PPR motif-containing protein, mitochondrial, also known as GP130 or 130 kDa leucine-rich protein, plays a pivotal role in RNA metabolism within both nuclear and mitochondrial matrices. It is involved in late stages of mRNA maturation, possibly associated with nuclear mRNA export, and in the stability or translation of mitochondrially encoded cytochrome c oxidase subunits. Additionally, it contributes to transcription regulation, including the regulation of multidrug-related genes MDR1 and MVP.
Therapeutic significance:
Given its involvement in Mitochondrial complex IV deficiency, nuclear type 5, a severe mitochondrial disease with multisystemic manifestations, understanding the role of Leucine-rich PPR motif-containing protein could open doors to potential therapeutic strategies.